Format

Send to

Choose Destination
J Thorac Oncol. 2013 May;8(5):e41-2. doi: 10.1097/JTO.0b013e31828bb1b3.

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

Author information

1
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA. rudin@jhmi.edu
PMID:
23524406
PMCID:
PMC3634121
DOI:
10.1097/JTO.0b013e31828bb1b3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center